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Abstract
Heparin and its low molecular weight heparin derivatives, widely used as clinical anticoagulants,
are acidic polysaccharide members of a family of biomacromolecules called glycosaminoglycans
(GAGs). Heparin and the related heparan sulfate are biosynthesized in the Golgi apparatus of
eukaryotic cells. Heparin is a polycomponent drug that currently is prepared for clinical use by
extraction from animal tissues. A heparin pentasaccharide, fondaparinux, has also been prepared
through chemical synthesis for use as a homogenous anticoagulant drug. Recent enabling
technologies suggest that it may now be possible to synthesize heparin and its derivatives
enzymatically. Moreover, new technologies including advances in synthetic carbohydrate
synthesis, enzyme-based GAG synthesis, micro- and nano-display of GAGs, rapid on-line
structural analysis, and microarray/microfluidic technologies might be applied to the enzymatic
synthesis of heparins with defined structures and exhibiting selected activities. The advent of these
new technologies also makes it possible to consider the construction of an artificial Golgi to
increase our understanding of the cellular control of GAG biosyntheses in this organelle.
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Heparin, a widely used anticoagulant, was introduced clinically soon after its discovery in
1916.1 For the next 70 years, it was the agent of choice for clinical anticoagulation. Heparin
is an acidic polysaccharide isolated by extraction from animal tissues including porcine
intestine.2 The heparin polysaccharide is a member of the glycosaminoglycan (GAG) family
and comprises a repeating disaccharide structure of 1→4-linked hexuronic acid and
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glucosamine saccharide residues (Fig. 1). It is highly sulfated and has an average molecular
weight of 10 to 15 kd.3 Although heparin exerts its anticoagulant effect in several ways, its
most well-understood activity involves binding to the serine protease inhibitor antithrombin
III (AT), which undergoes a conformational change, making it a potent inhibitor of thrombin
and other serine proteases (i.e., factor [F] Xa) important in the blood coagulation cascade.4
During the last 30 years, low molecular weight heparins (LMWHs) have been under
extensive development as improved anticoagulant agents.5 Several LMWHs have been
approved for clinical use and have begun to replace heparin as the clinical anticoagulant of
choice.6 These LMWHs have a major advantage when compared with heparin: they are
subcutaneously bio-available, resulting in their improved pharmacodynamics and allowing
their application on an outpatient basis.5,6
CURRENT LIMITATIONS FOR DEVELOPMENT OF THE NEXT GENERATION
OF AGENTS
LMWHs still retain several problems also associated with heparin, despite the major
improvements associated with their introduction. Both heparin and LMWHs are prepared
from animal sources, raising concerns about viral and prion-based contamination,2,6 and
limiting the amount of drug that can be produced easily.2 Heparin and LMWHs are also
polydisperse, polycomponent, polypharmacologic agents, making the analysis and control of
these drugs difficult.1,5,6 Finally, both heparin and LMWHs can cause severe side effects
such as hemorrhage and heparin-induced thrombocytopenia (HIT).7
Recognizing the limitation of these polycomponent drugs, a homogenous synthetic
pentasaccharide, fondaparinux, was developed and introduced (Arixtra, GSK, Brentford,
UK) that binds AT specifically and inhibits the serine protease inhibitor FXa.8
Fondaparinux, which has been approved for clinical use, has not been a commercial success.
The chemical synthesis of fondaparinux is both complicated and costly,9 and the high cost
of fondaparinux has not been justified by pharmacologic improvements compared with
heparin and LMWHs.8,10 Furthermore, fondaparinux still retains the major side effect of
hemorrhage and carries a slight risk of HIT.10 Other synthetic heparin analogs under
development are also unlikely to be successful without major improvements in the field of
synthetic carbohydrate chemistry.11
The need for improved heparin-based anticoagulants still remains. An ideal agent would (1)
not be derived from animal sources; (2) be relatively inexpensive to prepare in amounts
suitable for the growing market in anticoagulant drugs; (3) be a single component or a
structurally defined multicomponent agent; (4) exhibit excellent bioavailability and
pharmacodynamic/pharmacokinetic profiles; and (5) show reduced side effects, particularly
with regard to hemorrhage and HIT. This article discusses recently developed enabling
technologies that might pave the way for the development of new heparin-based
anticoagulants beyond the LMWHs. These enabling technologies include major advances in
(1) our understanding of GAG biosynthesis; (2) chemical carbohydrate synthesis; (3)
enzyme-based GAG synthesis; (4) micro-and nano-display of GAGs; (5) online GAG
analysis; and (6) microarray and microfluidic platforms.
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The next generation of anticoagulants should show nearly ideal chemical, biochemical, and
pharmacological properties to ensure their development as pharmaceuticals within the next
few decades. Finally, a platform useful for preparing such carbohydrate-based anticoagulant
agents would represent a form of artificial Golgi, and as such, would provide an improved
understanding of the biosyntheses of heparin and the closely related GAG, heparan sulfate
(HS), within the cell as well as the underlying controls of GAG biosynthesis.
GAG BIOSYNTHESIS
Lindahl et a112 have studied heparin/HS biosynthesis extensively. Heparin and HS are
structurally similar in that all of the disaccharide units found in heparin are also observed in
HS and all of the disaccharide units found in HS are also observed in the heparin.13
Moreover, several extended sequences, such as high/low-sulfated domains and the AT-
binding site (Fig. 1), can be found in both heparin and HS.14 Heparin and HS differ
primarily in the amount of each disaccharide that they contain.13 For example, in HS, D-
glucuronic acid is the major uronic acid, more than half of the glucosamine residues are N-
acetylated, and there is an average of one sulfo group per disaccharide. In contrast, heparin
has higher concentrations of α-L-iduronic acid and N-sulfo-β-D-glu-cosamine residues, and
an average of two to three sulfo groups per disaccharide.13 Heparin and HS contain at least
10 different sugar units,13,15 complicating efforts to sequence these polysaccharides.16–20
Similar biosynthetic pathways process heparin and HS.12,21–23 First, the core protein is
synthesized and then a tetrasaccharide linker is attached to specific serine residues.24,25
From this linkage, a repeating 1→4 glycosidically linked copolymer of β-D-glucuronic acid
and N-acetyl-β-D-glucosamine, called heparosan, is synthesized through the stepwise
addition of uridine di-phosphate (UDP) -activated sugars.12 Heparosan can also be
biosynthesized by bacteria, including Escherichia coli and Pasteurella multocida.26,27
During its synthesis in animal cells, the heparosan linear homocopolymer is modified
sequentially through the action of N-deacetylase/N-sulfotransferase, C-5 epimerase, and 2-,
6-, and 3-O-sulfotransferases (OSTs). Complete or nearly complete modification of this
nascent GAG chain results in a highly N- and O-sulfo—modified, α-L-iduronic acid—rich
GAG called heparin.3 Partial modification of the same chain results in an N-acetyl-β-D-
glucosamine, β-D-glucuronic acid—rich GAG called HS.25,29 All of the enzymes involved in
the biosynthesis of heparin and HS have been cloned and expressed. Many of these
biosynthetic enzymes (i.e., 3-OST, 6-OST) have multiple isoforms30–33 that show temporal-
and tissue-specific expression.32,34 Despite these major advances in our understanding of
GAG biosynthesis, it is still unclear how biosynthesis is controlled (i.e., extent, type of chain
modification, and domain placement).21,29
Heparin is biosynthesized as a proteoglycan called serglycin,24 and pharmaceutical heparin
generally is obtained from animal tissues rich in serglycin-containing mast cells,35 including
porcine intestine or bovine lung. Pharmaceutical heparin, commercially prepared in metric
ton quantities, ranges in molecular weight from 5000 to 40,000, with an average molecular
weight of 12,000.1,2
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Limitations in the Chemical Synthesis of Heparin
Despite recent advances,11,36 the total chemical synthesis of heparin, heparin
oligosaccharides, and derivatives using current state-of-the-art techniques, has serious
limitations. The multiple steps required by Sinaӱ9 and van Boecke137 to chemically
synthesize an intricately substituted heparin oligosaccharide, although it displays elegant
chemistry,9,36,37 results in a product that simply costs too much. Indeed, much synthetic
work has focused on simplifying the target structure (i.e., replacing 2-amino-2-deoxy-D-
glucose with D-glucose to prepare active analogs)11,37–39 rather than optimizing the synthesis
of the natural product. Although recent advances in the chemical synthesis of heparin
oligosaccharides by Thollas et a1,40 Jacquinet et a1,41 Prabhu et a1,42 Lohman et a1,43
Orgueira,44 and others45–47 have decreased the number of synthetic steps, increased
stereocontrol, and enhanced yields, each new target still represents a major research
commitment. Despite problems inherent to the chemical synthesis of heparin
oligosaccharides, the synthetic AT-binding pentasaccharide, fondaparinux, was introduced
as a clinical anticoagulant in both the United States and Europe.8 Although the approval of
fondaparinux represents a drug development success, the commercial outlook for this
expensive product is not bright.
Prospects for Synthetic UDP Sugars in Enzymatic Synthesis of GAGs
UDP sugar donors, UDP-N-acetylglucosamine and UDP-glucuronic acid, are routinely used
in the laboratory for studying heparin/HS biosynthesis.23 Recently, unnatural UDP
monosaccharide donors have been synthesized and used successfully to study the structure
—activity relationship of an antibiotic glycosides, such as vancomycin.48 Other unnatural
UDP monosaccharide donors, such as UDP-iduronic acid, UDP-2-azidoglucose, UDP-N-
trifluoroacetylglucosamine, and donors containing trifluoroethyl (TFE) -protected sulfo
groups,49 are currently under intensive investigation (Fig. 2). Although it is unclear if
synthases/glycoltransferases will accept all of these unnatural donors in place of their natural
UDP-N-acetylglucosamine and UDP-glucuronic acid substrates, preliminary studies
demonstrate that UDP-N-trifluor-oacetylglucosamine is readily accepted in place of UDP—
N-acetylglucosamine. Modeling of donors with neutral TFE-protected sulfo groups suggests
that they can be accommodated by synthases/glycosyltransferases. These unnatural UDP
donors can be synthesized chemically, by glycosylation of activated sugar with UDP, or
enzymatically from the 1-phosphosugar. Given that these donors contain only a single
glycosidic linkage, their synthesis in multiple-gram amounts is relatively uncomplicated,
suggesting the potential application of these unnatural UDP donors in the preparation of
chemo-enzymatically synthesized heparins.
ENZYME-BASED GAG SYNTHESIS
Synthase-Catalyzed Preparation of Unsulfated GAGs
Polysaccharide synthases are the glycosyltransferase enzymes that catalyze the
polymerization of activated sugars to form GAGs (Table 1).50–52 Synthase activity typically
is associated with either the plasma membrane (in prokaryotes) or the Golgi apparatus
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membranes (in eukaryotes). Some species of pathogenic bacteria take advantage of the
endogenous role of GAGs in cell—cell interaction and cellular communication in their
animal hosts. The bacteria form surface coatings (polysaccharide capsules) that comprise
GAGs identical or chemically similar to host molecules.53 Certain pathogenic strains of E.
coli and P. multocida make capsules composed of polymers very similar to HS. These
GAG-like polymers are not immunogenic and protect the bacteria from host defenses.
Indeed, these microbes use their GAGs as molecular camouflage.
Membrane-bound synthase/glycosyltransferase proteins are difficult to handle, thus, few
enzymes have been identified through biochemical purification. A larger number of
synthases/glycosyltransferases have been sequenced at the nucleotide level, cloned, and
expressed. Despite these advances, molecular details on their three-dimensional native
structures, active sites, and catalytic mechanisms are very limited. The exploration of these
enzymes for GAG synthesis is just beginning in our laboratories,54 but a few of these
catalysts have been harnessed as practical chemoenzymatic tools.
Enzyme Catalyzed Synthesis of Sulfated GAGs
The HS biosynthetic enzymes have been expressed in E. coli as truncated (no
transmembrane domain) fusion proteins using a bacterial cell line that coexpresses a
chaperone.59–60 Chaperones help recombinant proteins fold correctly to obtain functional
proteins. These recombinant proteins have comparable specific enzymatic activities and
substrate specificity of those expressed in mammalian and insect cells.
Enzymatically Designing the Functions of Heparin/HS
An enzymatic approach has been developed to synthesize heparin from completely
desulfonated N-sulfonated heparin. Although this clearly is not a viable commercial
approach, it serves to demonstrate that much of the technology is in hand to synthesize
heparin chemo-enzymatically. Only three enzymatic steps are required for the synthesis of
heparin with anticoagulant activity from desulfonated N-sulfonated heparin (Fig. 3), The
current study demonstrates two major advances that may permit the large-scale synthesis of
heparin. First, large amounts of all the required OST enzymes have been expressed
successfully in E. coli (as described) and immobilized on solid supports packed into
bioreactors. Second, a 3′-phosphoadenosine-5′-phosphosulfate (PAPS) regeneration system,
developed by Burkart et al,61 has been coupled to the enzymatic synthesis reactions. This
PAPS regeneration system alone reduces the cost of the synthesis by more than 1000-fold,
making the large-scale enzymatic synthesis possible.55
PAP (3′,5′-phosphoadenosine) is formed when the sulfo group is transferred to an acceptor.
A PAPS regeneration system converts PAP to PAPS through the action of recombinant
arylsulfotransferase-IV, which catalyzes the transfer of sulfo group from p-nitrophenyl
sulfate (PNPS) to PAP (Fig. 3B).61 This system is essential for the large-scale synthesis for
the following reasons. First, PAP inhibits the HS OSTs with concentration that inhibits 50%
values of ~100 µM, making milligram-scale synthesis difficult without continuously
removing PAP.55 Second, a PAPS regeneration system permits the PNPS as the sulfo donor
and catalytic amounts of PAP, consequently reducing the cost of synthesis.
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The PAPS regeneration system performs very well with immobilized 2-OST, 6-OST, and 3-
OST-1. Under the standard conditions, 2-OST, 6-OST, and 3-OST-1 afforded 98%, 97%,
and 98% complete modification, respectively. The incorporation of 2-O-sulfo and 6-O-sulfo
groups can be confirmed using disaccharide analysis of the structures of the newly
synthesized poly-saccharide products 2, 3 and 4a and 4b. Approximately 1.5 mg of AT-
binding HS (5, sec Fig. 1) was synthesized from 10 mg of completely desulfated N-sulfated
(CDSNS) heparin (1) using this approach.55
Synthesized polysaccharide intermediates were digested with a mixture of heparin lyases,
and the resulting disaccharides were analyzed using reversed-phase ion-pair partition high-
performance liquid chromatography.55 Analysis of 1 showed a disaccharide component of
the structure of ΔUAP-GlcNPS (ΔUA is 4-dcoxy-α-L-threo-hex-4-enopyranosyluronic acidp
is pyranoside), residual unsulfated disaccharide, ΔUAP-GlcNpAc, and small amounts of
sulfated disaccharides due to incomplete chemical desulfonation (Table 2). The modification
by 2-OST elevated the level of ΔUAP2S-GlcNpS by ~ 5-fold (Table 3), confirming the
structure of 2. Analysis of 3 afforded a 7-fold increase in the level of the disaccharide
ΔUAP-GlcNpS6S compared with 1, consistent with 6-OST catalyzed modification (Table 2).
The level of trisulfodisaccharide, ΔUAp2S-GlcNPS6S in 4a and 4b, was increased by ~ 10-
fold compared with that of 1 (Table 2). These results clearly establish that the expected
enzymatic modifications took place at each step. It is interesting to note that 6-O-sulfation
occurs at N-sulfo-glucosamine, consistent with the substrate specificity of 6-OST in vitro.62
The 2-O-sulfation occurs predominantly at the uronic acid with an N-sulfoglucosamine
residue at the reducing end. Interestingly, substantial amounts of ΔUAP-GlcNpS remain in
4a and 4b. This observation is not unexpected given that the HS from various tissues also
contain ΔUAp-GlcPNS disaccharide unit, suggesting that the structures of 4a and 4b are
similar to HS from natural sources. 1H-nucelar magnetic resonance analyses on these
polysaccharides were found to be consistent with the disaccharide analysis.55
Characterization of the affinities of AT to heparin and enzymatically modified heparin
derivatives (1–5) relied on surface plasmon resonance (SPR).55 A two-state reaction model
was applied to the SPR study. None of the derivatives, with the exception of the 2,6,3-O-
sulfo polysaccharide (5) and heparin, had high affinity to AT. The binding constant (KD) for
the binding of 2,6,3-O-sulfo polysaccharide 5 to AT was 170 nM, comparable to that of
pharmaceutical heparin (75 nM).
Because it is known that the introduction of the 3-O-sulfo group by 3-OST-1 is essential for
the synthesis of anticoagulant heparin, the FXa and thrombin activities of polysaccharides 5,
6, and 7 were evaluated (Table 3). As expected, heparin was a potent activator for AT-
mediated inhibition of FXa and thrombin, whereas fondaparinux specifically activates the
AT-mediated inhibition of FXa.47 Polysaccharide 5 has very similar potency to heparin,
inhibiting the activities of both FXa and thrombin, suggesting that an enzyme-based
approach is indeed capable of synthesizing an anticoagulant heparin poly-saccharide. It has
been reported that the presence of 2-O-sulfo groups is not essential for HS binding to AT
and its resulting anticoagulant activity.63 Indeed, polysaccharide intermediate 7 lacks 2-O-
sulfo groups but still exhibits anticoagulant activity, consistent with a previous report.63 In
contrast, 6 lacks 6-O-sulfo groups, and thus has no anticoagulant activity, given that 6-O-
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sulfo groups are critical in AT binding.64 The AT binding affinities of the synthesized
polysaccharides were also determined (Table 3), demonstrating that the anticoagulant
activities of the compounds correlated to their binding affinity to AT. Taken together, these
results demonstrate that the structure and anticoagulant activities of the enzymatically
synthesized polysaccharide 5 were consistent with the known structure and activity of
heparin (Fig. 1).
ON-LINE GAG ANALYSIS
Recent advances in mass spectrometry suggest that it is now possible to analyze intact
heparin/HS chains. Electrospray ionization mass spectrometry (MS), useful as an on-line
analytical tool, has been used effectively to analyze heparin oligosaccharides of molecular
mass as high as 7 kd.65 MS-MS methods allow for the positioning of sulfo groups within the
GAG chain.66 Electron capture dissociation—MS can be used to differentiate iduronic acid
from glucuronic acid residues.67 These advances in MS analysis should be applicable to the
real time analysis of polysaccharide chains synthesized in microfluidic devices. In addition,
the recent use of matrix-assisted laser desorption ionization (MALDI)-MS for the direct
analysis of uncomplexed sulfated oligosaccharides on a target surface68,69 suggests that it
might be possible to use MALDI-MS for the analysis of heparin/HS on the surface of a
microarray synthesizer (described in “Microarrays”).
MICRO- AND NANO-DISPLAY OF GAGs
Solid-phase synthesis of biopolymers offers the same advantage as it does in peptide
synthesis, maximizing yields and minimizing separation problems.70 Although heparin and
heparin oligosaccharides have been coupled to macroscopic supports such as affinity
resins71 for several years, such chemistry has only recently been applied to nano-based
carriers.71,72 The size of such nanocarriers resembles the dimensions of the core protein of
heparin/HS proteoglycans (Fig. 4). These nanoglycoconjugates are soluble72 in buffer
solutions, allowing their movement in microfluidic systems. Furthermore, nanocarriers such
as gold73 and quantum dots74 exhibit optical properties that facilitate their detection and
analysis. These rapidly developing technologies suggest the use of nanocarriers as solid
supports for the enzyme-based synthesis of heparin in microfluidic reactors. GAGs can be
synthesized on a solid phase (plastic, glass, metal, etc.) using enzyme catalysts.75
MICROARRAY AND MICROFLUIDIC PLATFORMS
Microarrays
Microarrays have been used for the screening of protein binding to heparin and heparin
oligosaccharides.76,77 The successful enzymatic modification of heparosan linked to a
surface78 suggests that it might also be possible to synthesize libraries of hcparins in a
micro-array format. A microarray of up to 5000 addressable spots can be printed on a glass
microscope slide.79 Each spot can be designed to contain a polysaccharide for modification
by C-5 epimerase and OSTs or an oligosaccharide for extension with glycosyltransferase
and subsequent enzymatic modification. Such a large micro-array could then he screened
and be probed with heparin-binding proteins. One might envision using microarrays to
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identify an enzymatically synthesized heparin able to bind AT and inhibit thrombin and FXa
without binding platelet factor 4, thus preventing HIT.80 Glycoanalysis of each microarray
spot would rely on MALDI-MS, and once characterized, a chain with desirable biochemical
and pharmacological properties could be synthesized in large scale for exploitation as a
novel pharmaceutical agent. Such devices might even be useful for introducing designer
heparins, fine-tuned to an individual patient. Such a pharmacogenetic approach requires a
high-throughput platform to be practicable.
Glycosylation Using Continuous-Flow Microfluidics
In early studies, Hernaiz et a178 demonstrated that 3-OST-1 could be used to convert
inactive HS (incapable of binding AT) into active (AT binding) HS in a microfluidic system.
On the basis of this initial success, four enzymes involved in heparin/HS biosynthesis were
cloned and expressed in E. coli. These enzymes were then used in solution-phase chemistry
to regenerate an active AT-binding site within a chemically modified heparin
polysaccharide.55 This approach was next extended to modify heparosan, a bacterial
capsular polysaccharide purified from E. coli K5, having the structure → 4)-α-D-N-
acetylglucosamine (1→ 4)-β-D-glucuronic acid (1→.56 This polysaccharide was chemically
de-N-acetylated and N-sulfonated to afford N-sulfoheparosan, having the structure → 4)-α-
D-N-sulfoglucosamine (1→ 4)-β-D-glucuronic acid (1→. N-sulfoheparosan was immobilized
onto a microfluid, flow cell-based, SPR sensor chip (Fig. 3). An interacting AT analyte was
flowed over the chip and AT-polysaccharide (ligand) binding was measured using SPR.78
As expected, AT failed to bind to N-sulfoheparosan because this ligand lacks the requisite
structure comprising the AT-binding site (Fig. 5).56,78 Biosynthetic enzymes and appropriate
cofactors, which had been applied previously to solution-phase syrithesis,55 were used to
modify the N-sulfohcparosan ligand immobilized to the surface of the microfluidic biosensor
chip. When the correct enzymes and cofactors were applied in the correct sequence, an AT-
binding site was introduced into the immobilized ligand. After this modification, the AT
analyte bound to the ligand on the biosensor chip with the expected affinity, confirming that
the biosynthetic enzymes were capable of acting in this micro-fluidic reactor. Unfortunately,
because there was insufficient control within the reactor, only a small number of the
resulting chains contained the desired AT binding site. Furthermore, the placement of this
site at a precise position within the chain could not be accomplished.
Related preliminary experiments have also demonstrated that heparin polysaccharides can
be immobilized covalently onto nanoparticle carriers and that enzymes are capable of acting
on the nanoparticle-immobilized polysaccharide.72 Furthermore, the heparin/HS
biosynthetic enzymes have been expressed as fission proteins, immobilized to solid supports
through their fusion protein domains, and demonstrate high stability and retention of
activity.55
FUTURE PROSPECTS
Glyosylation in the Golgi
The Golgi is an intracellular stack of membrane-hounded vesicles, responsible for the
modification and packaging of secreted proteins.81 This organelle is the subcellular entity
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controlling all glycosylation in eukaryotes (Fig. 6). With the successful determination of
multiple genomes and the ongoing successes in proteomics, the comprehensive study of
carbohydrate/glycan structure-function relationships, also known as glycomics, is
considered the last frontier in the biomacromolecular sciences. A unique feature of
glycomics is that there does not exist a straightforward correlation between the glycome and
the proteome or genome. Unraveling the multifaceted relationships among the glycome,
proteome, and genome is difficult because the extremely complex process of glycan
synthesis within the Golgi is not well understood. The primary obstacles to understanding
are (1) the intricate and fluid structural organization of this organelle; (2) the complex
trafficking of molecules (enzymes, chaperones, cofactors, and substrates) within the Golgi
and between the Golgi and the endoplasmic reticulum (the organelle responsible for protein
bio-synthesis and the initial steps in glycosylation); (3) a limited understanding of the
regulation and interplay between glycan biosynthetic enzymes; and (4) the difficulties
associated with elucidating glycan structure and function.
Among the most important glycoconjugates biosynthesized in the Golgi are proteoglycans.
An improved understanding of hcparan/HS biosynthesis will lead inevitably to an improved
understanding of normal and pathophysiological processes. This under-standing will
contribute to the solution of both historic and emerging health problems in the 21st century.
Controlled artificial synthesis of heparin/HS is extremely challenging because they are the
most structurally complex biopolymcrs in nature. Their biosynthesis in the Golgi involves
the condensation of nucleotide sugars on specific serine residues within a core protein and
the subsequent modification (re-modeling) of the growing polysaccharide chain through the
action of membrane-bound enzymes. This is the most complex example of glycan
biosynthesis, involving as many as 20 different enzymes found in multiple isoforms, and
these enzymes are differentially expressed in a spatial and temporal fashion within all
animals. Moreover, the underlying coordination of these biosynthetic enzymes within the
Golgi (i.e., as complexes, in specific compartments, on templates, with chaperones, etc.,) is
not well understood. An improved understanding of the parameters that control glycan
synthesis is needed, including controlled access of enzymes to protein-core—containing
oligosaccharide acceptors, assembly of multienzymc complexes, and access to cofactors and
substrates.
Research currently is underway to construct an artificial Golgi using microfluids for the
controlled synthesis of heparin on nanosupports and using on-line product analysis (Fig. 7).
Such a system will require additional development and integration of all of the enabling
technologies discussed in this article. The resulting device will serve as both a test device for
the understanding of Golgi function and regulation as well as a reactor for the generation of
structurally defined heparins with discrete biological activities.
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Primary structure and structural variability of a heparin chain with high affinity for
antithrombin III (AT). GlcNp, glucosamine; ldoAp, iduronic acid; GlcAp, glucuronic acid; S,
sulfo; Ac, acetyl.
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Natural and unnatural uridine diphosphate donors.
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Schematic synthesis of sulfonated polysaccharides and 3′-phosphoadenosine-5′-
phosphosultate (PAPS) regeneration system. (A) The stepwise enzymatic synthesis of
sulfonated polysaccharides using heparan sulfate (HS) sulfotransferases. The description of
intermediate polysaccharides is shown in the text. Compounds 4a and 4b were prepared by
inverting the order of sulfonation steps. 4a was prepared by incubating compound 1 with 2-
O-sullotransferase (2-OST) followed by 6-OST, whereas 4b was prepared by incubating
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compound 1 with 6-OST followed by 2-O5T. (B) The reaction catalyzed by
arylsulfotransferase IV to generate PAPS.
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A schematic of a heparin glycosaminoglycan chain immobilized to a carbon nanotube.
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Solid-phase synthesis of heparin from N-sulfoheparosan. Epi, ???; OST, O-sulfotransferase;
AT, antithrombin III.
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Simplified drawing of the Golgi. Core protein (gray ball) is biosynthesized in the
endoplasmic reticulum (ER), glycosylation is initiated and core protein decorated with
oligosaccharide acceptor is transferred in budded transport vesicle along microtubule tracks
to the Golgi (some retrieval from the Golgi by the ER is also possible). As the glycoprotein
moves through the Golgi stacks (cis to medial to trans), the glycan chain (black line) is
elongated and elaborated. Mature glycoprotein exits the trans Golgi in vesicles for transport
to the cell surface (some removal of excess or damaged glycoprotein takes place through
lysosomal degradation).
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Schematic representation of an artificial Golgi.
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Table 1
Acidic Glycosaminoglycan (GAG) Synthases/Glycosyltransferases and Substrates
GAG Species GAG-Transferases UDP Donors Acceptors
Hyaluronan Vertebrates Class I HAS 1,2,3 GlcNAc, GlcA (GlcNAc-GlcA)n ≥ 1
(GlcA-GlcNAc)n ≥ 1
Streptococcus Class I spHAS
Chlorella Class I cvHAS
Virus
Pasteurella Class II pmHAS GlcNAc, GlcA
Chondroitin Vertebrates ChSy GalNAc, GlcA (GalNAc-GlcA)n ≥ 1
(GlcA-GalNAc)n > 1
Pasteurella pmCS, KfoC GalNAc, GlcA
Escherichia
Hyaluronan/chondroitin Recombinant chimeric pmHAS/pmCS GalNAc (HexNAc-GlcA)n ≥ 1
GlcN, GlcNAc, GlcA (GlcA-HexNAc)n ≥ 1
Heparan Vertebrates EXT 1,2 GlcNAc, GlcA (GlcNAc-GlcA)n ≥ ?
(GlcA-GlcNAc)n ≥ 1
Heparosan Pasteurella pmHS 1,2 GlcNAc, GlcA (GlcNAc-GlcA)n ≥ 11
(GlcA-GlcNAc)n > 1
Escherichia KfiA + KfiC (2 proteins needed) GlcNAc, GlcA
UDP, uridine diphosphate; HAS, hyaluronan synthase; GlcNAC, N-acetylglucosamine; GlcA, glucuronic acid; ChSy, chondroitin synthase; CS,
chrondroitin sulfate; Hs, heparan sulfate.
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Table 3










Heparin‡ 20 10 ND
HS§ > 5000 > 3000 ND
Fondaparinux‖ 58 > 3000 ND
6 > 2000 > 3000 5%
7 126 96 31%
5 40 32 38%
*
The procedures for measuring the activities of factor Xa and thrombin are described elsewhere.1
†
3-O-[35S]sulfo compounds were used to determine their bindings to AT as described elsewhere. 13H-labeled HS from CHO cells was used as a




HS was isolated from bovine kidney.
‖
Fondaparinux is the chemically synthesized antithrombin-binding pentasaccharide, which was obtained from local pharmacy.
IC50, concentration that inhibits 50%; HS, heparan sulfate; ND, not determined.
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